# Semaglutide: GLP-1 Receptor Pharmacology and Clinical Evidence — Clinic Semaglutide > Semaglutide binds GLP-1 receptors across pancreatic, hypothalamic, and enteric tissues — producing a 14.9% mean body weight reduction and 20% cardiovascular risk reduction in Phase 3 trials. The mechanism and evidence, cited. A mechanistic and clinical-evidence digest for the compound with the largest Phase 3 trial program in its drug class. Every quantitative claim drawn from the published literature — cited, attributed, and organized. ## What the Semaglutide literature has established Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1 (GLP-1), engineered with structural modifications that extend plasma half-life from the native hormone's ~2 minutes to approximately 168 hours — enabling once-weekly subcutaneous dosing. The compound's evidence base is the largest of any GLP-1 receptor agonist, spanning six named trial series (SUSTAIN, PIONEER, STEP, SELECT, ESSENCE, OASIS) plus active Phase 3 work in metabolic-associated steatohepatitis, alcohol use disorder, and adolescent obesity. The headline numbers are well-characterized. Subcutaneous semaglutide at 2.4 mg weekly produced a mean 14.9% body weight reduction versus 2.4% with placebo over 68 weeks in adults without type 2 diabetes — 86.4% of treated participants achieved at least 5% weight loss [1]. In cardiovascular outcome research, the SELECT trial enrolled 17,604 adults with obesity and established cardiovascular disease and found a 20% relative reduction in the composite risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.80, 95% CI 0.72–0.90) over a mean 39.8 months [2]. Semaglutide is FDA-approved for three distinct indications: type 2 diabetes management (subcutaneous, 2017; oral, 2019), chronic weight management in adults with obesity or overweight plus a weight-related condition (subcutaneous 2.4 mg, 2021), and — as of 2025 — metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. The adolescent weight management indication (≥12 years) was approved in 2022. This site documents the pharmacological mechanism, the clinical trial record, and the pharmacokinetic profile. It does not sell, prescribe, or dispense semaglutide in any form. ## What Is Semaglutide? Semaglutide is a peptide drug — a 31-amino-acid GLP-1 receptor agonist that is an analogue of human glucagon-like peptide-1, sharing approximately 94% structural homology with the native hormone. Three deliberate structural modifications define the compound's pharmacokinetics. First, the amino acid at position 8 is substituted with alpha-aminoisobutyric acid (Aib), which shields that residue from DPP-4 enzyme cleavage — the mechanism by which native GLP-1 is degraded in plasma within minutes. Second, lysine at position 34 is replaced with arginine to prevent GIP cross-reactivity. Third, a C18 fatty diacid chain is attached via a flexible linker to lysine at position 26, enabling reversible albumin binding in plasma. Albumin binding dramatically slows renal clearance and provides further steric protection against DPP-4 — the combined effect produces the ~168-hour terminal half-life [13]. The result is an oral-or-injectable peptide that acts at GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract with far greater potency and duration than native GLP-1. [semaglutide GLP-1 receptor agonist](/mechanism#glp1-receptor) pharmacology is detailed on the mechanism page. ## Regulatory Status of Semaglutide Semaglutide carries multiple FDA approval milestones across different formulations and indications. Subcutaneous semaglutide was approved for type 2 diabetes management in December 2017, at doses of 0.5 mg and 1.0 mg once weekly. An oral formulation was approved in September 2019 at 7 mg and 14 mg daily for type 2 diabetes — the first oral GLP-1 receptor agonist to reach approval, enabled by co-formulation with the SNAC absorption enhancer. The 2.4 mg subcutaneous dose for chronic weight management in adults was approved in June 2021, followed by the adolescent indication (≥12 years) in 2022. An investigational 7.2 mg dose demonstrated greater weight loss in the STEP UP trial (2025) [17]. In August 2025, FDA approved the 2.4 mg subcutaneous formulation for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis — the first GLP-1 agonist approval for liver disease — following Phase 3 ESSENCE trial results showing 62.9% MASH resolution versus 34.3% placebo [8]. Semaglutide is not on the WADA Prohibited List as of 2024. ## Semaglutide as a Peptide Compound Semaglutide belongs to the peptide drug class — it is a chain of 31 amino acids, not a small molecule. This distinction has practical consequences: the compound cannot be absorbed orally without an absorption enhancer (SNAC, in the oral formulation), and it does not cross the blood-brain barrier efficiently via passive diffusion — its central nervous system effects on appetite are mediated via circumventricular organs and hypothalamic projections that lack a complete blood-brain barrier. At a molecular weight of 4,113.6 Da, semaglutide is larger than most injectable pharmaceuticals but smaller than biologic antibodies. Its status as a peptide shapes its manufacturing (solid-phase peptide synthesis followed by fatty-acid conjugation), its storage requirements (refrigerated, solution-based pre-filled pens for subcutaneous use), and its degradation pathway (proteolytic cleavage, not hepatic CYP450 metabolism — explaining the clean drug-drug interaction profile) [15]. This site focuses on semaglutide's pharmacology as a peptide GLP-1 receptor agonist. See the [semaglutide mechanism of action](/mechanism) page for full receptor-binding and signaling pathway detail. ## Semaglutide Research Indications The published research covers five active indication areas, with the MASH and addiction findings representing 2024–2025 expansions of the compound's evidence base. **Type 2 diabetes:** The SUSTAIN trial series (SUSTAIN-1 through SUSTAIN-10) established semaglutide's glycemic efficacy and cardiovascular safety in type 2 diabetes. SUSTAIN-6 demonstrated a 26% reduction in MACE in 3,297 high-cardiovascular-risk T2D patients (HR 0.74, 95% CI 0.58–0.95) [3]. **Obesity and chronic weight management:** The STEP trial series (STEP 1 through STEP 8, TEENS, UP) characterizes semaglutide's weight management profile, with consistent mean weight loss in the 14–19% range across studies. [semaglutide for weight loss](/weight-loss) is covered in detail on the dedicated page. **Cardiovascular outcomes:** SELECT enrolled 17,604 adults with obesity without diabetes; the primary MACE outcome reduction (20%, HR 0.80) established semaglutide as a cardiovascular risk-reducing agent independent of glycemic action [2]. **MASH/MAFLD:** ESSENCE (N=1,197, 2025) documented 62.9% MASH resolution versus 34.3% placebo — the first Phase 3 GLP-1 trial to show reversal of both steatohepatitis and liver fibrosis [8]. **Addiction and CNS:** A 2025 Phase 2 randomized controlled trial (N=48) demonstrated significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder [9], supported by preclinical mechanistic work showing modulation of GABA neurotransmission in the amygdala and infralimbic cortex [10]. --- A generative reading of the GLP-1 receptor pharmacology record — mechanism, trials, and pharmacokinetics, cited from the literature.